Pediatric obesity — Pharmacotherapy prior authorization
Customize your policy alerts
Sign up for allcareadvantage Policy 040.1 alerts
Get alerted when Policy 040.1 changes without checking for updates manually.
Monitor payer policy activity
Governs prior authorization and coverage criteria for formulary FDA‑approved medications for pediatric weight loss for AllCare Advantage members up to age 20, including approval and renewal requirements.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial approval criteria
Covered when ALL of the following are met
If severity not documented, do not approve; forward to MD for review.
If not met, do not approve; forward to MD for review.
If BMI <95th percentile, do not approve; forward to MD for review.
If not documented, do not approve; forward to MD for review.
Renewal criteria
Renewal covered when ALL of the following are met
If not, review under initial criteria.
If not met, do not approve; forward to MD for review.
This policy applies to prior authorization requests for formulary, FDA‑approved medications for pediatric weight loss for AllCare Advantage members. Coverage is limited to patients whose treatment is for conditions funded by the Oregon Health Plan and must be consistent with the Health Evidence Review Commission (HERC) Prioritized List of Health Services. In addition, the medical condition must be of sufficient severity to impact the patient’s health (for example: quality of life, function, growth, development, ability to participate in school, or perform activities of daily living).
Do not approve requests when the documented data do not meet required clinical thresholds or prior‑treatment requirements. Specifically, do not approve if the member’s BMI is below the 95th percentile; if there is no documentation that conservative non‑pharmacologic measures have been attempted and failed (including documented motivational interviewing); or if documentation does not show completion of at least 26 hours of Individual/Group Health Behavior Lifestyle Training (IHBLT) within the prior 12 months. Also do not approve when the requested medication is not FDA‑approved for the submitted or comorbid diagnoses and is not supported by appropriate compendia of current literature. When these conditions are not met, route the request for denial or to a medical reviewer as specified in the clinical workflow.
Key Eligibility Metrics
Provider Actions & Documentation
Prior authorization required
Formulary medications that are approved for pediatric weight loss require prior authorization prior to dispensing; members must meet the policy criteria before the drug is dispensed.
Non‑pharmacologic measures required first
Prior to approving pharmacotherapy, the policy requires documented failure of conservative non‑pharmacologic measures consistent with clinical practice guidelines, including documented motivational interviewing and completion of IHBLT.
- Documented failure of motivational interviewing
- Documentation of at least 26 hours of Individual/Group Health Behavior Lifestyle Training (IHBLT) within the last 12 months
Required documentation
Provide documentation that the medical condition is of sufficient severity to impact the member's health and that eligibility criteria are met before approval.
- Evidence the condition impacts health (examples: quality of life, function, growth, development, ability to participate in school, activities of daily living)
- BMI documentation showing ≥95th percentile
- Evidence the requested drug is FDA‑approved for the submitted/comorbid diagnoses or supported by appropriate compendia
- Documentation of failed motivational interviewing
- Documentation of ≥26 hours of IHBLT in the prior 12 months
Triggers for denial
Do not approve (deny) when required documentation or prerequisites are missing or not met, per the policy's denial triggers.
- No documentation that the condition impacts the patient's health (e.g., quality of life, function, growth, development, school participation, activities of daily living)
- BMI <95th percentile
- Motivational interviewing not documented or not failed
- Less than 26 hours of IHBLT documented in the prior 12 months
- Requested medication is not FDA‑approved for the diagnosis and lacks compendia support
Background
Childhood obesity places children and adolescents at increased risk for poor health outcomes. Pharmacotherapy is reserved for older children and adolescents and should be considered only after conservative measures have failed. Per the policy’s clinical rationale, pharmacologic treatment is intended for patients aged 12 years and older who have a BMI ≥95th percentile and who have failed guideline‑concordant, non‑pharmacologic interventions. Prior authorization is required and the provider must document the severity of disease, prior behavioral interventions, and medication appropriateness before therapy is approved.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.